Alfuzosin (10 mg) Does Not Affect Blood Pressure in Young Healthy Men

ObjectivesAlfuzosin 10 mg is a uroselective α1-adrenoceptor antagonist used to treat lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Recent studies have suggested the potential efficacy of alfuzosin in the treatment of distal ureteral stones and prostatitis syndrome, two conditions frequently encountered in young patients. The objective of this study was to evaluate the effect of 10 mg alfuzosin on blood pressure (BP) and heart rate (HR) in young healthy volunteers.Materials and methodsIn a randomized, double-blind, placebo-controlled, crossover study, the effect of alfuzosin 10 mg on BP and HR was evaluated in 14 male volunteers (mean age: 28 yr; range: 24–30). BP < 135/85 obtained in two separated measurements was a main inclusion criterion. Patients were then randomized to alfuzosin (10 mg once a day) or placebo for 1 wk, followed by a washout week, and then crossed over to the other treatment. Patients were instructed to self-measure systolic (SBP) and diastolic (DBP) blood pressure and HR every hour between 8 am and 8 pm during the first and the last day of each cycle treatment.ResultsAll 14 enrolled volunteers completed the study. No significant difference in either SBP, DBP, or HR was observed between the placebo and alfuzosin groups at baseline. Alfuzosin did not affect SBP, DBP, or HR. No hypotensive episode (SBP reduction >10%) was recorded during each treatment.ConclusionsThis study shows that alfuzosin 10 mg is well tolerated by young healthy subjects and may therefore be safely administered to young normotensive patients affected by distal ureteral stones and prostatitis.